Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients

Inclusion Criteria

• •Received a minimun of 6 months therapy with with belimumab 10 mg/kg in their current SLE belimumab continuation study.
• •Be 18 years of age at the Day 0 visit.
• •Non-prenant, non-lactating females willing to comply with specific birth control requirements as set forth in the protocol.
• •Able to provide written informed consent to participate.
• •Subjects who wish to enroll in the control group and the group taking a 6 month belimumab treatment holiday will need a SELENA SLEDAI score of 3 or less after the minimum of 6 months belimumab therapy, as well as having C3 and C4 complement levels at or above the lower limit of the central laboratory reference range, and are on a stable SLE treatment regimen during the 30 day screening period prior to Day 0.
• •Subjects who wish to enroll in the long-term discontinuation group have voluntarily withdrawn from their continuation studies.